Your browser doesn't support javascript.
loading
Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients.
Fossard, Gaëlle; Blond, Emilie; Balsat, Marie; Morisset, Stéphane; Giraudier, Stéphane; Escoffre-Barbe, Martine; Labussière-Wallet, Hélène; Heiblig, Maël; Bert, Arthur; Etienne, Madeleine; Drai, Jocelyne; Sobh, Mohamad; Redonnet-Vernhet, Isabelle; Lega, Jean-Christophe; Mahon, François-Xavier; Etienne, Gabriel; Nicolini, Franck Emmanuel.
Afiliación
  • Fossard G; Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite.
  • Blond E; Laboratory of biochemistry, Centre Hospitalier Lyon Sud, Pierre Bénite INSERM U1060, CarMeN Laboratory, Lyon 1 University, INRA 1235, Oullins.
  • Balsat M; Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite.
  • Morisset S; Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite.
  • Giraudier S; Laboratory of Hematology, Hôpital Henri Mondor, Créteil Groupe Fi-LMC, Hôpital Haut Lévêque, Pessac, France.
  • Escoffre-Barbe M; Hematology department, Hôpital Pontchaillou, Rennes Groupe Fi-LMC, Hôpital Haut Lévêque, Pessac, France.
  • Labussière-Wallet H; Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite.
  • Heiblig M; Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite.
  • Bert A; Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite.
  • Etienne M; Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite Groupe Fi-LMC, Hôpital Haut Lévêque, Pessac, France.
  • Drai J; Laboratory of biochemistry, Centre Hospitalier Lyon Sud, Pierre Bénite INSERM U1060, CarMeN Laboratory, Lyon 1 University, INRA 1235, Oullins.
  • Sobh M; Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite.
  • Redonnet-Vernhet I; Laboratory of biochemistry, Hôpital Pellegrin, Bordeaux.
  • Lega JC; Internal medicine department, Centre Hospitalier Lyon Sud, Pierre Bénite.
  • Mahon FX; Département d'hématologie, Institut Bergonié, Bordeaux Groupe Fi-LMC, Hôpital Haut Lévêque, Pessac, France.
  • Etienne G; Département d'hématologie, Institut Bergonié, Bordeaux Groupe Fi-LMC, Hôpital Haut Lévêque, Pessac, France.
  • Nicolini FE; Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite Inserm U1052, Centre de Recherche en Cancérologie de Lyon Groupe Fi-LMC, Hôpital Haut Lévêque, Pessac, France franck-emmanuel.nicolini@chu-lyon.fr.
Haematologica ; 101(3): e86-90, 2016 Mar.
Article en En | MEDLINE | ID: mdl-26635034
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Pirimidinas / Enfermedad de la Arteria Coronaria / Leucemia Mieloide de Fase Crónica / Hiperhomocisteinemia / Mesilato de Imatinib / Antineoplásicos Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2016 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Pirimidinas / Enfermedad de la Arteria Coronaria / Leucemia Mieloide de Fase Crónica / Hiperhomocisteinemia / Mesilato de Imatinib / Antineoplásicos Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2016 Tipo del documento: Article